New Drug Combination Before Surgery for Advanced Prostate Cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests whether combining four drugs (chemotherapy, hormone therapy, and a new medicine) before surgery can help men with aggressive prostate cancer. The goal is to shrink tumors and improve outcomes before the prostate is surgically removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age between 18 and 85 years old
- Prostate cancer confirmed by biopsy or tissue sample
- Advanced/aggressive prostate cancer (advanced stage, high Gleason score, high PSA level, or spread to distant sites)
- Good overall health and able to tolerate treatment (ECOG score 0-1)
- Willing to sign consent and complete all treatment and follow-up visits
- No previous prostate cancer treatment (surgery, radiation, chemotherapy, or hormone therapy)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of three treatments (darolutamide, docetaxel, and hormone therapy) given before surgery for men with locally advanced prostate cancer that hasn't spread. The goal is to see if this approach is safe and effective in shrinking the cancer before surgery.
This trial tests giving a new hormone-blocking drug (darolutamide) plus standard hormone therapy before surgery for men with high-risk prostate cancer that has not spread. The goal is to see if this approach improves outcomes.
This trial tests a combination of a targeted radioactive drug (177Lu-PSMA-617) and a hormone blocker (Darolutamide) given before surgery for high-risk prostate cancer that hasn't spread. The goal is to see if this approach can improve outcomes.
This trial tests a combination of darolutamide (a hormone-blocking pill) and standard hormone therapy (ADT) given before prostate surgery. It is for men with high-risk prostate cancer that has not spread to distant parts of the body, to see if the treatment can improve outcomes.
This trial tests darolutamide (a hormone blocker pill) with or without standard hormone therapy given before surgery for high-risk prostate cancer. The goal is to see if this combination can shrink the cancer and improve outcomes before the prostate is removed.
This trial tests a combination of hormone therapy, a targeted pill (Darolutamide), and an immunotherapy drug (Pembrolizumab) before and after surgery for men with high-risk prostate cancer that has specific genetic features. The goal is to see if this approach helps prevent the cancer from coming back.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.